Montelukast Viatris (Montelukast)

Montelukast blocks the cysteinyl leukotriene receptor CysLT1, preventing leukotrienes D4, E4 and related molecules from binding. This inhibition reduces bronchoconstriction, mucus production, and airway inflammation, helping to keep the airways open and less reactive.

The specific dose of Montelukast Viatris is determined by the prescribing healthcare professional based on the patient’s age, condition and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Montelukast in pregnancy and lactation are limited. Healthcare providers weigh potential benefits against risks before prescribing it to pregnant or nursing individuals. Patients should discuss their situation with a qualified professional before use.

To request Montelukast Viatris, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Montelukast belongs to the leukotriene receptor antagonist class, offering an oral alternative to inhaled corticosteroids or long‑acting beta‑agonists. It is particularly useful for patients with allergic components or those who prefer a once‑daily tablet, but it may be less potent for acute symptom relief compared with inhaled bronchodilators.

Montelukast Viatris should be stored at room temperature, below 25 °C, in its original packaging. Keep the product away from moisture, direct sunlight and extreme heat to maintain its stability and potency.

Montelukast Viatris is taken orally, usually as a tablet swallowed whole with water. It is typically taken once daily in the evening, but the exact timing and administration instructions are provided by the prescribing clinician.

Serious risks include rare allergic reactions such as angioedema or Stevens‑Johnson syndrome, and neuropsychiatric events like depression, anxiety, or suicidal thoughts. Patients should seek immediate medical attention if they experience swelling of the face or throat, skin rash, or significant mood changes.

Montelukast Viatris should be avoided in individuals with known hypersensitivity to montelukast or any of its excipients. Caution is also advised for patients with severe hepatic impairment or those taking medications that strongly induce CYP3A4, unless directed by a healthcare professional.